Revolution Medicines (RVMD) Revenue & Revenue Breakdown
Revolution Medicines Revenue Highlights
Latest Revenue (Y)
$11.58M
Main Segment (Y)
Collaboration Revenue Member
Revolution Medicines Revenue by Period
Revolution Medicines Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $11.58M | -67.27% |
| 2022-12-31 | $35.38M | 20.38% |
| 2021-12-31 | $29.39M | -31.62% |
| 2020-12-31 | $42.98M | -14.10% |
| 2019-12-31 | $50.04M | 148.16% |
| 2018-12-31 | $20.16M | 100.00% |
| 2017-12-31 | - | - |
Revolution Medicines generated $11.58M in revenue during NA 2023, up -67.27% compared to the previous quarter, and up 57.43% compared to the same period a year ago.
Revolution Medicines Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $742.00K | 100.00% |
| 2023-09-30 | - | -100.00% |
| 2023-06-30 | $3.82M | -45.48% |
| 2023-03-31 | $7.01M | -54.25% |
| 2022-12-31 | $15.33M | 356.79% |
| 2022-09-30 | $3.36M | -63.19% |
| 2022-06-30 | $9.12M | 20.30% |
| 2022-03-31 | $7.58M | -19.89% |
| 2021-12-31 | $9.46M | 759.22% |
| 2021-09-30 | $1.10M | -87.34% |
| 2021-06-30 | $8.70M | -14.14% |
| 2021-03-31 | $10.13M | 15.77% |
| 2020-12-31 | $8.75M | -30.88% |
| 2020-09-30 | $12.66M | 26.29% |
| 2020-06-30 | $10.03M | -13.17% |
| 2020-03-31 | $11.55M | -4.48% |
| 2019-12-31 | $12.09M | -3.34% |
| 2019-09-30 | $12.51M | 1.83% |
| 2019-06-30 | $12.28M | -6.72% |
| 2019-03-31 | $13.17M | 27.24% |
| 2018-12-31 | $10.35M | - |
Revolution Medicines generated - in revenue during Q4 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Revolution Medicines Revenue Breakdown
Revolution Medicines Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|
| Collaboration Revenue Member | $35.38M | $29.39M | - |
| Collaboration Revenue Related Party | - | - | $42.98M |
Revolution Medicines's latest annual revenue breakdown by segment (product or service), as of Dec 22: Collaboration Revenue Member (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue Member | $7.01M | $15.33M | $3.36M | $9.12M | $9.46M | - | - | - | - | - | - | - | - |
| Collaboration Revenue | - | - | - | - | $7.58M | $1.10M | $8.70M | $10.13M | - | - | - | - | - |
| Collaboration Revenue Related Party | - | - | - | - | - | - | - | - | - | $8.75M | $12.66M | $10.03M | $11.55M |
Revolution Medicines's latest quarterly revenue breakdown by segment (product or service), as of Mar 23: Collaboration Revenue Member (100.00%).
Revolution Medicines Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue Member | $7.01M | $15.33M | $3.36M | $9.12M | $9.46M | - | - | - | - | - | - | - | - |
| Collaboration Revenue | - | - | - | - | $7.58M | $1.10M | $8.70M | $10.13M | - | - | - | - | - |
| Collaboration Revenue Related Party | - | - | - | - | - | - | - | - | - | $8.75M | $12.66M | $10.03M | $11.55M |
Revolution Medicines's latest quarterly revenue breakdown by geography, as of Mar 23: Collaboration Revenue Member (100.00%).
Revolution Medicines Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| KYMR | Kymera Therapeutics | $78.59M | $10.29M |
| NRIX | Nurix Therapeutics | $76.99M | $12.09M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| AGIO | Agios Pharmaceuticals | $26.82M | $8.62M |
| RVMD | Revolution Medicines | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| FIXX | Q32 Bio | $1.16M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| BDTX | Black Diamond Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| PASG | Passage Bio | - | - |
| SANA | Sana Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| AKRO | Akero Therapeutics | - | - |
RVMD Revenue FAQ
What is Revolution Medicines’s yearly revenue?
Revolution Medicines's yearly revenue for 2023 was $11.58M, representing a decrease of -67.27% compared to 2022. The company's yearly revenue for 2022 was $35.38M, representing an increase of 20.38% compared to 2021. RVMD's yearly revenue for 2021 was $29.39M, representing a decrease of -31.62% compared to 2020.
What is Revolution Medicines’s quarterly revenue?
Revolution Medicines's quarterly revenue for Q4 2023 was $0, a -100.00% decrease from the previous quarter (Q3 2023), and a -100.00% decrease year-over-year (Q4 2022). The company's quarterly revenue for Q3 2023 was $742K, a 100.00% increase from the previous quarter (Q2 2023), and a -95.16% decrease year-over-year (Q3 2022). RVMD's quarterly revenue for Q2 2023 was $0, a -100.00% decrease from the previous quarter (Q1 2023), and a -100.00% decrease year-over-year (Q2 2022).
What is Revolution Medicines’s revenue growth rate?
Revolution Medicines's revenue growth rate for the last 3 years (2021-2023) was -60.60%, and for the last 5 years (2019-2023) was -76.86%.
What are Revolution Medicines’s revenue streams?
Revolution Medicines's revenue streams in c 22 are Collaboration Revenue Member
What is Revolution Medicines’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Revolution Medicines was Collaboration Revenue Member. This segment made a revenue of $35.38M, representing 100.00% of the company's total revenue.